exv10w13w5






EXHIBIT 10.13.5




     XXXXX INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.



EXECUTION COPY




February 9, 2007




Impax Laboratories, Inc.

30831 Huntwood Avenue

Haywood, California 94544

Attention: Larry Hsu, Ph.D., President




Dear Dr. Hsu:



Reference is made to the Strategic Alliance Agreement, effective June 27, 2001, between Teva
Pharmaceuticals Curacao N.V. (“Teva”) and Impax Laboratories, Inc. (“Impax”), as amended to date
(collectively, the “Agreement”). All capitalized terms used herein, and not otherwise defined
herein, shall have the respective meanings set forth in the Agreement.



This shall confirm that effective as of the Effective Date, as defined in the Omnibus Agreement by
and among Teva, Impax, Anchen Pharmaceuticals, Inc. (“Anchen”) and Biovail Laboratories
International SRL (“Biovail”) dated the same date hereof concerning finished bupropion
hydrochloride extended release tablets (“Omnibus Agreement”), Teva and Impax agree as follows
(notwithstanding the foregoing, Teva and Impax hereby agree that if the Transaction Agreements (as
defined in the Omnibus Agreement) become null and void pursuant to Section 3.4 of the Omnibus
Agreement, this letter agreement shall also become null and void effective as of the date hereof):



(1) The Impax Margin with respect to the Bupropion Products shall be revised and, accordingly,
Section 1.1(b) of the amendment between Teva and Impax dated January 24, 2006 (“Amendment”) shall
be deleted in its entirety and replaced with the following:




“; provided further, however, that with respect to the Bupropion Products, such amount
shall be equal to:




(a) for the Impax Products, a percentage of the Profit according to the following chart:



 









 





EXECUTION COPY




	 	 	 
	PERIOD	 	IMPAX MARGIN
	Commencing on the Launch Date and ending three (3)
months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing three (3) months from the Launch Date and
ending six (6) months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing six (6) months from the Launch Date and
ending nine (9) months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing nine (9) months from the Launch Date and
ending twelve (12) months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing twelve (12) months from the Launch Date
and thereafter

	 	XXXXX% of the Profit








(b) for the Anchen Products XXXXX, XXXXX percent (XXXXX%) of
the Profit.”






(2) Teva hereby grants to Impax a non-exclusive sublicense
(XXXXX)
to all license rights granted from Biovail to Teva under the License Agreement by and between Teva
and Biovail dated the same date hereof (the “Biovail License Agreement”) to the extent necessary
for Impax to manufacture and supply to Teva the Impax Products to the extent such rights are
provided to Teva in the Biovail License Agreement.






(3) Teva shall have sole discretion to decide to Market at any time XXXXX. Further,
Teva shall have the discretion to decide to XXXXX. In the event that Teva XXXXX for purposes of Section 2.21
of the Agreement, and for purposes of determining the Impax Margin payable with respect thereto.
The term XXXXX.





(4) Teva warrants that in the event that it launches a XXXXX.




 









 





EXECUTION COPY






(5) Clause (2) of the proviso added by Section 1.1(e) of the Amendment, and revised by the letter
agreement between Teva and Impax dated September 13, 2006 with respect to the 150mg Bupropion
Products, shall be deleted in its entirety as it relates to the 150mg Bupropion Products and shall
read as follows: “all amounts paid by Teva and/or its Affiliates to Anchen and Biovail (or their
respective affiliates).”



(6) Impax agrees on behalf of itself and its Affiliates that none of them shall, directly or
indirectly, in any regulatory, judicial or other forum, challenge or contest the first to file
exclusivity for the 150mg Ancben,Product.



(7) Teva represents and warrants on behalf of itself and its Affiliates that it is unaware of any
fact that would form a basis to challenge the first to file exclusivity for the 150mg Anchen
Product.



The Agreement, as amended by the foregoing, shall remain in full force and effect. This letter
agreement shall be a legally binding agreement between Teva and Impax. This letter agreement may
be executed in two or more counterparts, each of which shall be deemed an original but all of
which, taken together, shall constitute one and the same instrument.


(Remainder of page intentionally left blank)



 









 







This letter agreement may be delivered by facsimile transmission and receipt of facsimile copy of any party’s signature shall be considered to be receipt of an original copy thereof.



Thank you.



Sincerely,



	 	 	 	 	 
	Teva Phartmaceuticals Curasco N.V.	 	 
	 
	 	 	 	 
	By:

	 	/s/ [Illegible]
	 	/s/ [Illegible]
	 

	 	 	 	 
	Name:
	 	 	 	 
	 

	 	 	 	 
	Title:

	 	Managing Director
	 	Managing Director
	 

	 	 	 	 





Read and Agreed to::

This 9th day of February, 2007



	 	 	 	 	 
	Impax Laboratories, Inc.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Larry Hsu
 

	 	 
	Name:

	 	Larry Hsu
 

	 	 
	Title:

	 	CEO/President